Details for Patent: 6,028,071

Summary for Patent: 6,028,071

Title:	Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Abstract:	Highly purified 10-propargyl-10-deazaaminopterin (10-propargyl-10dAM) compositions tested in xenograft models for their efficacy against human tumors are shown to be far superior to methotrexate ("MTX") and are even superior to the newer clinical candidate edatrexate ("EDX"). Moreover, 10-propragyl-10dAM showed a surprising ability to cure tumors such that there was no evidence of tumor growth several weeks after the cessation of therapy. Thus, highly purified compositions containing 10-propargyl-10dAM can be used to treat human tumors, particularly human mammary tumors and human lung cancer.
Inventor(s):	Sirotnak; Francis M. (New York, NY), Piper; James R. (Birmingham, AL), DeGraw; Joseph I. (Missoula, MT), Colwell; William T. (Menlo Park, CA)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY) SRI International (Menlo Park, CA) Southern Research Institute (Birmingham, AL)
Application Number:	09/214,984
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,028,071
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 6,028,071

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,028,071

PCT Information
PCT Filed	July 16, 1997	PCT Application Number:	PCT/US97/11982
PCT Publication Date:	January 22, 1998	PCT Publication Number:	WO98/02163

International Family Members for US Patent 6,028,071

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	407677
Canada	2260266
Germany	69738981
Denmark	0944389
European Patent Office	0944389